X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs IPCA LABS - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA IPCA LABS ASTRAZENECA PHARMA/
IPCA LABS
 
P/E (TTM) x 61.1 26.0 234.9% View Chart
P/BV x 17.2 4.4 391.1% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 ASTRAZENECA PHARMA   IPCA LABS
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
IPCA LABS
Mar-18
ASTRAZENECA PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,278695 183.8%   
Low Rs883400 220.7%   
Sales per share (Unadj.) Rs228.4260.2 87.8%  
Earnings per share (Unadj.) Rs10.419.0 54.6%  
Cash flow per share (Unadj.) Rs16.333.1 49.2%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs98.8213.0 46.4%  
Shares outstanding (eoy) m25.00126.20 19.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.72.1 224.7%   
Avg P/E ratio x104.228.9 361.1%  
P/CF ratio (eoy) x66.416.6 401.0%  
Price / Book Value ratio x10.92.6 425.4%  
Dividend payout %05.3 0.0%   
Avg Mkt Cap Rs m27,00869,120 39.1%   
No. of employees `0001.413.3 10.2%   
Total wages/salary Rs m1,5357,359 20.9%   
Avg. sales/employee Rs Th4,210.92,477.4 170.0%   
Avg. wages/employee Rs Th1,132.2555.2 203.9%   
Avg. net profit/employee Rs Th191.1180.6 105.8%   
INCOME DATA
Net Sales Rs m5,71032,836 17.4%  
Other income Rs m123418 29.3%   
Total revenues Rs m5,83333,254 17.5%   
Gross profit Rs m4634,505 10.3%  
Depreciation Rs m1471,777 8.3%   
Interest Rs m0240 0.0%   
Profit before tax Rs m4382,905 15.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m179511 35.0%   
Profit after tax Rs m2592,394 10.8%  
Gross profit margin %8.113.7 59.1%  
Effective tax rate %40.817.6 232.2%   
Net profit margin %4.57.3 62.2%  
BALANCE SHEET DATA
Current assets Rs m3,20919,455 16.5%   
Current liabilities Rs m2,07010,076 20.5%   
Net working cap to sales %20.028.6 69.9%  
Current ratio x1.61.9 80.3%  
Inventory Days Days7298 73.9%  
Debtors Days Days3567 52.2%  
Net fixed assets Rs m79020,260 3.9%   
Share capital Rs m50252 19.8%   
"Free" reserves Rs m2,41926,633 9.1%   
Net worth Rs m2,46926,886 9.2%   
Long term debt Rs m02,340 0.0%   
Total assets Rs m4,60541,173 11.2%  
Interest coverage xNM13.1-  
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.20.8 155.5%   
Return on assets %5.66.4 87.9%  
Return on equity %10.58.9 117.8%  
Return on capital %17.710.8 164.8%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m30015,642 1.9%   
Fx outflow Rs m2,0154,884 41.3%   
Net fx Rs m-1,71510,759 -15.9%   
CASH FLOW
From Operations Rs m883,411 2.6%  
From Investments Rs m-94-1,354 6.9%  
From Financial Activity Rs mNA-1,304 0.0%  
Net Cashflow Rs m-6753 -0.8%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 11.4 2.6%  
FIIs % 15.7 25.3 62.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.4 52.3%  
Shareholders   12,856 36,892 34.8%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   DR. DATSONS LABS  STRIDES PHARMA SCIENCE  FDC LTD.  JUBILANT LIFE SCIENCES  BIOCON   

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 267 Points Lower; Metal and Capital Goods Stocks Witness Huge Selling(Closing)

India share markets continued to witness selling pressure during closing hours and ended their day deep in the red. At the closing bell, the BSE Sensex stood lower by 267 points (down 0.7%).

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

The Perfect Stock in the Rebirth of India(The 5 Minute Wrapup)

Aug 8, 2019

This debt-free, well-managed company is all set to soar.

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Super investor Pulak Prasad is Buying Stocks Big Time...and You Should Too(The 5 Minute Wrapup)

Aug 9, 2019

Here's why the relentless correction in the Indian stock markets has not unnerved the big investors.

Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

Qatar is Rearing Cows...this is Good News for India

Aug 9, 2019

Qatar has turned around after the Saudi embargo. This is good news for India.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Aug 21, 2019 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS